Mart-1 Antigen
Intraocular Melanoma
University of Southern CaliforniavaccinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
64 Active assets in the Intraocular Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifa Craig L Slingluff, Jr | Phase 2 | BBB |
Tyrosinase Peptide University of Southern California | Phase 3 | BB |
Sargramostim Thomas Jefferson University | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 2/3 | BB |
Gm-Csf Ahmad Tarhini | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Mart-1 Antigen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →